Watson Recalls Caziant Tablets Due to Out-of-Specification Impurities
Watson Laboratories is recalling Caziant tablets because out-of-specification results were obtained for a known impurity.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Watson Laboratories, Inc. is recalling Caziant (desogestrel and ethinyl estradiol) Tablets, USP, (Triphasic Regimen). The recall involves 63,627 cartons of the medication, which are distributed nationwide. The specific products affected are identified by the following lot codes and expiration dates: 432127A (Exp. 01/13), 478076A (Exp. 05/13), and 515539B (Exp. 09/13).
The recall was initiated because out-of-specification results were obtained for a known impurity. The FDA has classified this recall as Class III, which indicates that use of or exposure to the violative product is not likely to cause adverse health consequences.
Consumers who have this product should contact their pharmacist or healthcare provider for guidance on how to dispose of the medication or obtain a replacement. The product is prescription-only, so patients should consult their prescriber regarding any changes to their medication regimen.
The recalled product
- Product
- Caziant (desogestrel and ethinyl estradiol) Tablets, USP, (Triphasic Regimen), 0.1 mg/0.025 mg, 0.125 mg/0.025 mg, 0.15 mg/0.025 mg, 28-count tablets per dispenser (NDC 52544-959-28), packaged in 3-count Tablet Dispensers per carton (NDC 52544-959-31), Rx only Manufactured by: Wa
- Manufacturer
- Watson Laboratories Inc
- Category
- Drug — Oral Contraceptive
- Hazard
- Affected units
- 63,627
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- 432127A Exp. 01/13
- 478076A Exp. 05/13
- 515539B Exp.09/13
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Watson Laboratories Inc
See all →- ModerateWatson Recalls Hydrocodone and Acetaminophen Tablets Due to Broken Tablets
FDA (Drugs) · 2014-02-05
- SevereWatson Recalls Carisoprodol Tablets Due to Metal Particulates
FDA (Drugs) · 2014-01-15
- ModerateWatson Recalls Next Choice Emergency Contraceptive Tablets Due to Breakage
FDA (Drugs) · 2013-10-16
- SevereWatson Recalls Oxycodone and Acetaminophen Tablets Due to Foreign Contamination
FDA (Drugs) · 2013-10-09
- LowWatson Recalls Hydrocodone and Acetaminophen Tablets Due to Defective Seals
FDA (Drugs) · 2013-09-25
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08